Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Introduction
Xilio Therapeutics, Inc. (symbol: XLO) is a clinical‐stage biotechnology company located in Waltham, Massachusetts. The company is dedicated to advancing tumor‐activated immuno‐oncology therapies that concentrate therapeutic activity within tumors while minimizing systemic toxicity. Utilizing a proprietary platform, Xilio creates innovative biologics such as engineered antibodies, cytokines, and chemokines with a focus on improving cancer treatment outcomes.
Core Technology and Proprietary Platform
At the heart of Xilio Therapeutics is its unique platform technology designed to selectively activate cancer therapies in the tumor microenvironment. The company’s approach centers on the concept of activating therapeutic molecules only when they reach the tumor site, a principle inspired by the Latin term ex nihilo, meaning a creation or big-bang event. This technology not only enhances the therapeutic index but also limits unwanted systemic side effects, setting the company apart in the realm of immuno‐oncology and protein engineering.
Therapeutic Pipeline and Modalities
Xilio is building a broad pipeline of novel immuno‐oncology molecules including tumor‐activated cytokines, antibodies (such as Fc‐enhanced anti‐CTLA-4 agents), and complex bispecifics. These therapeutics are engineered to deliver focused anti-tumor activity directly within the tumor microenvironment, thereby reprogramming “cold” tumors into “hot” ones that are more responsive to immunotherapy. Among its candidate programs are investigational therapies that leverage approaches like tumor-activated IL-12 and beta-gamma biased IL-2 variants, which are designed to stimulate anti-tumor immune responses while reducing toxicities typically associated with systemic cytokine therapies.
Clinical Development and Collaborations
Xilio Therapeutics operates as a clinical-stage biotech, meaning that its products are in early to mid-stage clinical development. The company actively conducts Phase 1 and Phase 2 trials, evaluating the safety, tolerability, and preliminary efficacy of its candidates in diverse patient populations with advanced solid tumors. Its clinical programs are structured to assess both monotherapy and combination therapy approaches. Collaborative agreements with major biopharmaceutical companies have provided additional validation and funding for its pipeline, and these partnerships help enhance the clinical development process by leveraging complementary expertise and resources.
Innovative Designs and Market Positioning
In a market crowded with immuno‐oncology initiatives, Xilio distinguishes itself with its tumor-activated approach. The use of masked molecules, antibody engineering enhancements, and conditional activation strategies positions its offerings as more targeted and potentially safer alternatives compared to conventional therapies. The company’s structure as a clinical-stage entity focused on translational research and early clinical validation underpins its significance in the evolving immunotherapy landscape.
Scientific Rationale and Operational Excellence
The scientific rationale behind Xilio’s programs is rooted in enhancing the local immune response against tumors while avoiding systemic immune activation that can lead to adverse events. This is achieved by engineering molecules that remain inert systemically until exposed to the unique environment provided by the tumor. The operational and technical expertise required to develop such therapies highlights the company’s advanced capabilities in protein engineering, immuno-oncology, and biopharmaceutical research. By continuously refining its platform and clinical strategies, Xilio demonstrates a commitment to solving complex challenges in cancer treatment without resorting to generalized approaches.
Partnerships and Collaborative Endeavors
Strategic partnerships are integral to Xilio’s business model. These collaborations with established entities in the biotechnology sector serve not only as a source of funding but also provide a collaborative framework for clinical trial design, regulatory navigation, and market strategy. Through these partnerships, Xilio leverages external expertise in tandem with its proprietary innovations to reinforce its market presence and accelerate the development of its pipeline candidates. Such collaborations also underscore the scientific community’s validation of the company’s unique mechanism of action.
Expertise, Experience, and Industry Impact
With a foundation built on decades of research in immuno‐oncology and advanced biologics, Xilio Therapeutics combines robust scientific expertise with significant operational experience. The detailed design of its tumor-activated therapies reflects a sophisticated understanding of both cancer biology and antibody engineering. This expertise is instrumental in addressing complex problems within the therapeutic landscape and laying the groundwork for a new generation of targeted cancer treatments.
Conclusion
In summary, Xilio Therapeutics is operating at the confluence of innovative science and strategic clinical development. Its commitment to harnessing localized immune activation within the tumor microenvironment positions it as a noteworthy participant in the fight against cancer. The company’s expansive pipeline, proprietary activation platform, and strategic partnerships illustrate an approach that is both precise and grounded in deep scientific expertise. Investors, industry analysts, and stakeholders can view Xilio Therapeutics as an embodiment of how next-generation immuno‐oncology strategies may transform cancer treatment while maintaining a focus on safety and efficacy.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced new employee stock option grants. The company granted non-qualified stock options to three new employees to purchase a total of 22,900 shares of common stock, effective April 1, 2025.
The stock options were issued under Xilio's 2022 Inducement Stock Incentive Plan with an exercise price of $0.7244 per share, matching the closing price on March 31, 2025. The options have a ten-year term and follow a vesting schedule of 25% after the first year, with the remaining 75% vesting in 36 monthly installments, contingent on continued employment.
Xilio Therapeutics (XLO) reported key pipeline and financial updates for Q4 and full year 2024. The company highlighted promising Phase 2 data for vilastobart, showing a 27% objective response rate in MSS CRC patients without liver metastases, with only 5% reporting colitis.
The company announced a significant collaboration with AbbVie in Q1 2025, receiving $52.0 million in upfront payments, including a $10.0 million equity investment, with potential for up to $2.1 billion in milestone payments plus royalties.
Financial highlights include: Cash position of $55.3 million as of December 31, 2024; License revenue of $6.3 million for 2024; R&D expenses decreased to $41.2 million from $52.1 million in 2023; Net loss improved to $58.2 million from $76.4 million in 2023. The company expects current cash runway into Q1 2026.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference.
The company's president and chief executive officer, René Russo, Pharm.D., will engage in a fireside chat on Monday, March 3, 2025, at 9:50 am EST.
Interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's investor relations website at ir.xiliotx.com. The webcast recording will remain available on the website for 30 days after the presentation.
Xilio Therapeutics (Nasdaq: XLO) announced three preclinical programs for masked T cell engagers targeting PSMA, CLDN18.2, and STEAP1. The company also entered into a collaboration agreement with AbbVie, receiving $52.0 million in upfront payments ($42.0M cash and $10.0M equity investment).
The collaboration includes an exclusive option for AbbVie to develop masked cell engager molecules and a license for masked antibody-based immunotherapy, with potential additional payments up to $2.1 billion plus tiered royalties. Xilio's technology aims to improve T cell engager tolerability through tumor-selective activation.
Development timelines include: PSMA candidate nomination in Q3 2025 (IND in Q1 2027), CLDN18.2 candidate in Q4 2025 (IND in Q2 2027), and STEAP1 candidate in H1 2026 (IND in H2 2027). The company's cash runway has been extended into Q1 2026.
AbbVie (ABBV) and Xilio Therapeutics (XLO) have announced a collaboration and option-to-license agreement to develop novel tumor-activated immunotherapies. The partnership leverages Xilio's proprietary technology for tumor-activated biologics, focusing on masked T-cell engagers and antibody-based immunotherapies.
The agreement includes $52.0 million in total upfront payments, with a $10.0M equity investment from AbbVie. Xilio is eligible to receive up to $2.1 billion in contingent payments for option-related fees and milestones, plus tiered royalties. The collaboration aims to combine AbbVie's oncology expertise with Xilio's tumor-activation technology to develop next-generation cancer treatments with minimized systemic adverse events.
AbbVie (ABBV) and Xilio Therapeutics (XLO) have announced a collaboration and option-to-license agreement to develop novel tumor-activated immunotherapies. The partnership leverages Xilio's proprietary technology platform for developing tumor-activated biologics, including masked T-cell engagers.
The collaboration aims to combine AbbVie's oncology expertise with Xilio's technology to create next-generation cancer treatments focused on tumor-selective activation while minimizing systemic adverse events. Under the agreement terms, Xilio will receive $52.0 million in total upfront payments, including a $10.0M equity investment, and will be eligible for up to $2.1 billion in contingent payments plus tiered royalties.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to four new employees. The grants, effective February 1, 2025, consist of non-qualified stock options to purchase 83,400 shares of common stock at an exercise price of $0.705 per share, matching the closing price on January 31, 2025.
The options have a ten-year term with a vesting schedule of 25% after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO) announced initial Phase 2 data for vilastobart (XTX101) combined with atezolizumab in treating metastatic microsatellite stable colorectal cancer (MSS CRC). The trial showed a 27% preliminary response rate in patients without liver metastases, with three partial responses including two confirmed ones.
Key findings include decreased levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA), along with improved clinical symptoms. Among 40 treated patients, the combination demonstrated a favorable safety profile with low immune-related adverse events and only 5% reporting colitis. Of the 18 patients evaluable for response, 11 without liver metastases showed promising results, with responses ongoing at data cutoff.
The company plans to report updated Phase 2 data in mid-2025 and is seeking partnership opportunities to expand development beyond the initial MSS CRC trial.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted a non-qualified stock option to a new employee. The option, effective January 1, 2025, allows for the purchase of 60,000 shares of common stock at an exercise price of $0.955 per share, matching the company's closing price on December 31, 2024.
The stock option has a ten-year term with a vesting schedule of 25% after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted a non-qualified stock option to its new Chief Legal Officer, Caroline Hensley. The option, effective January 1, 2025, allows for the purchase of 375,000 shares of common stock at an exercise price of $0.955 per share, matching the company's closing price on December 31, 2024.
The stock option has a ten-year term with a vesting schedule where 25% of shares vest after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
What is the primary focus of Xilio Therapeutics?
How does Xilio differentiate its technology in cancer treatment?
What types of therapeutic modalities are under development at Xilio?
What role do clinical collaborations play in Xilio's strategy?
How has Xilio positioned itself within the competitive immuno-oncology landscape?
Why is the tumor microenvironment important in Xilio's approach?
